NO20023218D0 - 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer - Google Patents
2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorerInfo
- Publication number
- NO20023218D0 NO20023218D0 NO20023218A NO20023218A NO20023218D0 NO 20023218 D0 NO20023218 D0 NO 20023218D0 NO 20023218 A NO20023218 A NO 20023218A NO 20023218 A NO20023218 A NO 20023218A NO 20023218 D0 NO20023218 D0 NO 20023218D0
- Authority
- NO
- Norway
- Prior art keywords
- group
- amino
- mono
- nicotinamide derivatives
- tyrosine kinase
- Prior art date
Links
- HTPCDVLWYUXWQR-UHFFFAOYSA-N 2-aminopyridine-3-carboxamide Chemical class NC(=O)C1=CC=CN=C1N HTPCDVLWYUXWQR-UHFFFAOYSA-N 0.000 title abstract 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title abstract 2
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0001930.7A GB0001930D0 (en) | 2000-01-27 | 2000-01-27 | Organic compounds |
| PCT/EP2001/000835 WO2001055114A1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023218D0 true NO20023218D0 (no) | 2002-07-02 |
| NO20023218L NO20023218L (no) | 2002-09-16 |
| NO323826B1 NO323826B1 (no) | 2007-07-09 |
Family
ID=9884488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023218A NO323826B1 (no) | 2000-01-27 | 2002-07-02 | 2-amino-nikotinamidderivater og deres anvendelse for fremstilling av farmasoytiske preparater, fremgangsmate for fremstilling av derivatene samt farmasoytiske preparater omfattende disse |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6624174B2 (no) |
| EP (2) | EP2168948B1 (no) |
| JP (1) | JP3894793B2 (no) |
| KR (1) | KR100554988B1 (no) |
| CN (1) | CN1216867C (no) |
| AT (1) | ATE452880T1 (no) |
| AU (1) | AU771626B2 (no) |
| BR (1) | BR0107805A (no) |
| CA (1) | CA2396590C (no) |
| CZ (1) | CZ20022582A3 (no) |
| DE (1) | DE60140860D1 (no) |
| ES (2) | ES2490191T3 (no) |
| GB (1) | GB0001930D0 (no) |
| HU (1) | HUP0204083A3 (no) |
| IL (2) | IL150481A0 (no) |
| MX (1) | MXPA02007319A (no) |
| NO (1) | NO323826B1 (no) |
| NZ (1) | NZ520005A (no) |
| PL (1) | PL356307A1 (no) |
| PT (2) | PT1259487E (no) |
| RU (1) | RU2296124C2 (no) |
| SK (1) | SK287426B6 (no) |
| WO (1) | WO2001055114A1 (no) |
| ZA (1) | ZA200205988B (no) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098065A1 (en) * | 2000-01-11 | 2009-04-16 | Avikam Harel | Composition and methods for the treatment of skin disorders |
| US7419428B2 (en) * | 2000-04-28 | 2008-09-02 | Igt | Cashless transaction clearinghouse |
| DE10023492A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| ATE448226T1 (de) | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
| AP1666A (en) | 2000-09-11 | 2006-09-29 | Chiron Corp | Quinolinone derivatives as tyrosine kinase inhibitors. |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| DE50213703D1 (de) * | 2001-05-08 | 2009-09-03 | Bayer Schering Pharma Ag | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| WO2004013102A1 (de) * | 2002-07-31 | 2004-02-12 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene |
| US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| TWI422583B (zh) | 2003-03-07 | 2014-01-11 | 參天製藥股份有限公司 | 具有以４-吡啶烷硫基為取代基之新穎化合物 |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| KR20060097000A (ko) * | 2003-09-23 | 2006-09-13 | 노파르티스 아게 | 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물 |
| MXPA06003164A (es) * | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinaciones de un inhibidor del receptor de vegf con otros agentes terapeuticos. |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| EP1682529A4 (en) | 2003-11-07 | 2010-06-30 | Novartis Vaccines & Diagnostic | PROCESS FOR SYNTHESIS OF CHINOLINONE COMPOUNDS |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| US7544703B2 (en) | 2004-02-17 | 2009-06-09 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
| DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US7507748B2 (en) * | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| US8597947B2 (en) | 2004-12-29 | 2013-12-03 | Hadasit Medical Research Services & Development Limited | Undifferentiated stem cell culture systems |
| ES2525684T3 (es) | 2004-12-29 | 2014-12-29 | Hadasit Medical Research Services And Development Ltd. | Sistemas de cultivo de células madre |
| WO2006093253A1 (ja) * | 2005-03-03 | 2006-09-08 | Santen Pharmaceutical Co., Ltd. | キノリルアルキルチオ基を有する新規環式化合物 |
| EP1864977B1 (en) | 2005-03-31 | 2015-07-29 | Santen Pharmaceutical Co., Ltd. | Novel cyclic compound having pyrimidinylalkylthio group |
| EP1888556B1 (en) | 2005-05-17 | 2011-10-26 | Novartis AG | Methods for synthesizing heterocyclic compounds |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| EP2772257A1 (en) | 2005-11-29 | 2014-09-03 | Novartis AG | Formulations of quinolinones |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| WO2008093674A1 (ja) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | キナーゼ阻害活性を有する新規チアジアゾール誘導体 |
| AU2008242106B2 (en) | 2007-04-18 | 2013-05-16 | Hadasit Medical Research Services And Development Ltd. | Stem cell-derived retinal pigment epithelial cells |
| US8148157B2 (en) * | 2008-01-07 | 2012-04-03 | Ortho-Clinical Diagnostics, Inc. | Reference, calibrator, or control composition of PIGF-1 and sFlt-1 |
| KR20100126553A (ko) * | 2008-03-26 | 2010-12-01 | 노파르티스 아게 | Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체 |
| ES2445517T3 (es) | 2008-08-27 | 2014-03-03 | Leo Pharma A/S | Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa |
| CN101676267B (zh) * | 2008-09-16 | 2012-12-26 | 江苏恒瑞医药股份有限公司 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
| KR20120093867A (ko) | 2009-09-10 | 2012-08-23 | 아이알엠 엘엘씨 | 비시클릭 헤테로아릴의 에테르 유도체 |
| AU2010303567B2 (en) | 2009-10-06 | 2016-06-09 | Millennium Pharmaceuticals, Inc | Heterocyclic compounds useful as PDK1 inhibitors |
| WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
| JP2013532149A (ja) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| WO2012120469A1 (en) | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
| KR101412794B1 (ko) * | 2011-07-27 | 2014-07-01 | 보령제약 주식회사 | 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| EP2846803B1 (en) * | 2012-05-08 | 2017-06-21 | Alpharmagen, LLC | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| RU2718054C2 (ru) | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Способ лечения нефропатии |
| ES2893374T3 (es) | 2014-02-21 | 2022-02-08 | Frost Biologic Inc | Amidas antimitóticas para el tratamiento de cáncer y de trastornos proliferativos |
| IL314417A (en) | 2014-12-30 | 2024-09-01 | Cell Cure Neurosciences Ltd | Assessing retinal pigment epithelial cell populations |
| EP3674397A1 (en) | 2014-12-30 | 2020-07-01 | Cell Cure Neurosciences Ltd. | Rpe cell populations and methods of generating same |
| WO2017017686A1 (en) | 2015-07-29 | 2017-02-02 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
| US11066642B2 (en) | 2015-08-05 | 2021-07-20 | Cell Cure Neurosciences Ltd | Preparation of retinal pigment epithelium cells |
| US11090337B2 (en) | 2015-08-05 | 2021-08-17 | Cell Cure Neurosciences Ltd | Preparation of photoreceptors for the treatment of retinal diseases |
| US10125118B2 (en) | 2015-08-31 | 2018-11-13 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as therapeutic drugs |
| WO2017072763A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
| CN110520139A (zh) | 2017-02-08 | 2019-11-29 | 哈达西特医疗研究服务和开发有限公司 | 用于治疗视网膜疾病的感光细胞 |
| US20200085882A1 (en) | 2017-03-16 | 2020-03-19 | Lineage Cell Therapeutics, Inc. | Methods for measuring therapeutic effects of retinal disease therapies |
| WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
| EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
| CA3112135A1 (en) | 2018-09-20 | 2020-03-26 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
| EP3754014A1 (en) | 2019-06-21 | 2020-12-23 | Centre d'Etude des Cellules Souches (CECS) | Automated method for preparing retinal pigment epithelium cells |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| JP2024522608A (ja) | 2021-06-09 | 2024-06-21 | リネージ セル セラピューティクス インコーポレイテッド | 網膜の疾患および症状を処置するための方法および組成物 |
| IL310156A (en) | 2021-07-28 | 2024-03-01 | Lineage Cell Therapeutics Inc | Expansion of retinal pigment epithelial cells |
| AU2023260469A1 (en) | 2022-04-25 | 2024-11-14 | Cell Cure Neurosciences, Ltd. | Methods and compositions for treating vision loss |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2058656T3 (es) * | 1989-04-20 | 1994-11-01 | Boehringer Ingelheim Pharma | 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida. |
| ES2167377T3 (es) * | 1993-10-01 | 2002-05-16 | Novartis Ag | Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos. |
| ATE384062T1 (de) | 1996-08-23 | 2008-02-15 | Novartis Pharma Gmbh | Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung |
| NZ337698A (en) | 1997-04-04 | 2001-07-27 | Pfizer Prod Inc | Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases |
| WO1998057957A1 (en) | 1997-06-18 | 1998-12-23 | Nissan Chemical Industries, Ltd. | Pyridine compounds and herbicides |
| AR013693A1 (es) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
| US6506747B1 (en) * | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| DE69931393T2 (de) | 1998-12-23 | 2007-03-29 | Eli Lilly And Co., Indianapolis | Antithrombotische amide |
| ES2391550T3 (es) | 1999-04-15 | 2012-11-27 | Bristol-Myers Squibb Company | Inhibidores cíclicos de la proteína tirosina quinasa |
| CA2397493A1 (en) | 2000-01-27 | 2001-08-02 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
-
2000
- 2000-01-27 GB GBGB0001930.7A patent/GB0001930D0/en not_active Ceased
-
2001
- 2001-01-25 SK SK1085-2002A patent/SK287426B6/sk not_active IP Right Cessation
- 2001-01-25 EP EP09179064.2A patent/EP2168948B1/en not_active Expired - Lifetime
- 2001-01-25 PT PT01946854T patent/PT1259487E/pt unknown
- 2001-01-25 US US10/181,005 patent/US6624174B2/en not_active Expired - Lifetime
- 2001-01-25 CN CN018042333A patent/CN1216867C/zh not_active Expired - Fee Related
- 2001-01-25 ES ES09179064.2T patent/ES2490191T3/es not_active Expired - Lifetime
- 2001-01-25 CA CA2396590A patent/CA2396590C/en not_active Expired - Lifetime
- 2001-01-25 BR BR0107805-4A patent/BR0107805A/pt not_active Application Discontinuation
- 2001-01-25 EP EP01946854.5A patent/EP1259487B8/en not_active Expired - Lifetime
- 2001-01-25 IL IL15048101A patent/IL150481A0/xx unknown
- 2001-01-25 RU RU2002121645/15A patent/RU2296124C2/ru not_active IP Right Cessation
- 2001-01-25 PT PT91790642T patent/PT2168948E/pt unknown
- 2001-01-25 KR KR1020027009671A patent/KR100554988B1/ko not_active Expired - Fee Related
- 2001-01-25 DE DE60140860T patent/DE60140860D1/de not_active Expired - Lifetime
- 2001-01-25 ES ES01946854T patent/ES2338407T3/es not_active Expired - Lifetime
- 2001-01-25 HU HU0204083A patent/HUP0204083A3/hu unknown
- 2001-01-25 NZ NZ520005A patent/NZ520005A/en not_active IP Right Cessation
- 2001-01-25 AT AT01946854T patent/ATE452880T1/de active
- 2001-01-25 AU AU28499/01A patent/AU771626B2/en not_active Ceased
- 2001-01-25 MX MXPA02007319A patent/MXPA02007319A/es active IP Right Grant
- 2001-01-25 WO PCT/EP2001/000835 patent/WO2001055114A1/en not_active Ceased
- 2001-01-25 JP JP2001555056A patent/JP3894793B2/ja not_active Expired - Lifetime
- 2001-01-25 CZ CZ20022582A patent/CZ20022582A3/cs unknown
- 2001-01-25 PL PL01356307A patent/PL356307A1/xx not_active Application Discontinuation
-
2002
- 2002-06-27 IL IL150481A patent/IL150481A/en not_active IP Right Cessation
- 2002-07-02 NO NO20023218A patent/NO323826B1/no not_active IP Right Cessation
- 2002-07-26 ZA ZA200205988A patent/ZA200205988B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023218L (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| DE69418704D1 (de) | Anthranilsäure derivate | |
| MX2007006821A (es) | Derivados de 2,4 (4,6) pirimidina. | |
| EP1396493A4 (en) | HETEROCYCLIC COMPOUNDS | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| BR0212829A (pt) | Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados | |
| DK0873319T3 (da) | Quinazolinderivater | |
| DK1261602T3 (da) | Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer | |
| DE60237145D1 (de) | Chinazolinderivate | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| NO20023161L (no) | Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem | |
| PT1165544E (pt) | 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| DK1340757T3 (da) | 1-methylcarbapenemderivater | |
| PT1315730E (pt) | Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona | |
| NO20022123L (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
| BR0209332A (pt) | Derivados de ftalazina com atividade inibidora da angiogênese | |
| NO20054495L (no) | Nye anilinderivater, deres fremstilling og anvendelse som farmasoytiske forbindelser | |
| NO983656L (no) | Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander | |
| NO20053302D0 (no) | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. | |
| CA2385244A1 (en) | Novel nicotinonitrile compounds | |
| TH55955A3 (th) | สารยับยั้งของ p38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |